2.43%XLF 15.10 
10.30%QQQQ 31.32 0.63%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
PRINCETON, N.J. - Biopharmaceutical company Bristol-Myers Squibb Co. said Wednesday the Hart-Scott-Rodino review period for its tender offer for cancer therapy maker Kosan Biosciences Inc. has expired.
Bristol-Myers Squibb initiated a tender offer through its KB Acquisition Corp. subsidiary last month to buy Kosan for $5.50 per share, or about $234.6 million.
The company said the end of the waiting period satisfies one of the conditions to the tender offer, which is set to expire on June 25.
Health officials are investigating an outbreak of a mystery disease in southern Africa which has so far claimed three lives.
The new soldiers in the upcoming prequel 'Halo 3: Recon' are "among the fiercest" in the popular game series, Microsoft says....
In last week's report, I held out the prospect that the US government rescue package might result in a change in sentiment in financial mark...
|
Professional Website Design For Corporate - Get a Free Quote Today
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
-0.42
0.13
